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The placenta is an endocrine organ capable of 
producing a wide range of hormones and other 
regulatory molecules, able to ensure endocrine 
and metabolic homeostasis in the mother and 
the fetus during pregnancy [1,2].
When these regulatory mechanisms are 
impaired, the following obstetrics syndromes 
may occur: preeclampsia (PE), intra uterine 
growth restriction (IUGR) and preterm 
 delivery (PTD).
PE is a multisystemic disorder, with unknown 
etiology, which occurs in approximately 2–8% 
of pregnancies and is responsible for significant 
maternal and fetal morbidity/mortality world-
wide. The multifactorial pathogenesis includes: 
failure of trophoblast invasion, oxidative stress, 
endothelial dysfunction and maternal circula-
tory impairment. A series of distinct molecular 
events occur at placentation, and consequently 
on the rest of gestation [3].
IUGR is the inability of the fetus to achieve its 
potential growth; it is described as a birth weight 
below the tenth percentile for gestational age 
and it is associated with high risk for perinatal 
morbidity and mortality [4]. It occurs in 2–5% 
of pregnancies and is often associated with PE.
PTD is one of the major obstetric  syndromes, 
with variable incidence from 7 to 15%, and 
it causes 35% of all neonatal deaths; it is 
characterized by a complex etiopathogenesis, 
where stress and inflammation represent major 
 mechanisms [5].
The obstetric syndromes are responsible for 
maternal death and perinatal morbidity and 
mortality [6,7]. In recent times, a common patho-
genetic mechanism underlying these obstetric 
diseases has been hypothesized. Placenta plays a 
major role in all these syndromes. In fact, defec-
tive deep placentation, representing the process 
of physiologic remodeling of the spiral arteries, 
was first found in preeclamptic placentas and 
in cases of IUGR; more recently, this abnormal 
process has also been related to PTD.
Placentation is a biological process in which 
fetal and maternal tissues develop into complex 
structures and uterine vasculature is profoundly 
remodeled. This physiologic transformation 
decreases peripheral vascular resistance in the 
placental bed, maximizing blood flow to the 
intervillous space. By contrast, failure of physi-
ologic transformation of the myometrial seg-
ment of the spiral arteries, probably through 
ischemia or inflammation, is considered involved 
in the pathophysiology of the main pregnancy 
syndromes [7–10].
As the placenta plays a major role in all these 
diseases, placental factors affect pathogenic 
mechanisms.
Filiberto Maria Severi1, 
Maria De Bonis1, 
Francesca Letizia 
Vellucci1, Chiara 
Voltolini1, Caterina 
Bocchi1, Mariarosaria 
Di Tommaso2, Michela 
Torricelli1 and Felice 
Petraglia*1
1Obstetrics and Gynecology, 
Department of Molecular and 
Developmental Medicine, University of 
Siena, Viale Bracci, 53100 Siena, Italy
2Department of Woman and Child’s 
Health, University of Florence, Florence, 
Italy
*Author for correspondence:  
Tel.: +39 0577 233 453  
Fax: +39 0577 233 454  
felice.petraglia@unisi.it
Preterm delivery, preeclampsia and intrauterine growth restriction are the major diseases of 
pregnancy. A key role in their pathogenesis is played by the placenta, which is the source of 
hormones and other important regulatory molecules providing the metabolic and endocrine 
homeostasis of the fetal–placental unit. Since obstetric syndromes are characterized by important 
maternal and neonatal morbidity and mortality worldwide, numerous efforts have been made 
over the years to prevent and treat them. Due to their complex pathogenesis, however, the 
therapy is poor and not very effective. Therefore, great emphasis is currently given to the 
prevention of these diseases through the identification of biochemical and biophysical markers, 
among which placental factors play a crucial role. The increasing knowledge of the role of 
placental molecules can indeed lead to the development of new therapeutic and diagnostic tools.
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Considering the impact of these syndromes on social, health 
and economic levels, numerous efforts have been made over the 
years to prevent and treat them. Therefore, starting from the 
studies on pathogenesis, several tools have been tested of potential 
usefulness for the early diagnosis before symptoms occur and 
eventually for the treatment of these disorders. Biological fluids 
such as maternal serum and plasma, saliva, urine, vaginal and 
amniotic fluid have always been investigated for the detection 
and measurements of placental molecules. In this way, it may be 
possible to use these molecules (steroids, neurohormones, peptides 
and glycoproteins) in order to better understand the pathogenic 
mechanisms of the main obstetric syndromes. Moreover, in recent 
decades, bio chemical markers have been joined by biophysical 
markers, encouraged by the continued scientific research in this 
field [11–13].
Despite the advances in medical research, there are still nonspe-
cific biochemical or biophysical markers that may predict these 
pregnancy complications, but the frequency of these diseases has 
not changed. Only the integration of patient’s anamnesis with the 
use of multiple biochemical and biophysical markers may help in 
identifying patients at risk.
The purpose of this review is to describe the most studied 
placental hormones in the main pregnancy complications and 
to identify the possible implications for their use in the clinical 
management and early detection of these diseases. To be effective, 
a screening marker needs to be sufficiently sensitive and specific 
and must provide an adequate positive-predictive value. Today, 
several promising markers have been described, alone or in com-
bination, that may fulfill these criteria in order to detect early 
changes responsible for the onset of the pregnancy pathologies 
and to be used as a therapeutic tool.
Preeclampsia
The major pathogenic mechanism responsible for preeclampsia is 
represented by abnormal placentation and vascularization, result-
ing in impaired trophoblast invasion (Figure 1). Abnormal placen-
tation, or defective deep placentation, is characterized by absent 
or incomplete remodeling of the junctional zone segment of the 
spiral arteries [14]. In normal pregnancy, a subset of cytotropho-
blast cells called ‘invasive cytotrophoblasts’ migrate through the 
implantation site and invade tunica media of maternal spiral arter-
ies, replacing its endothelium in a process called ‘pseudovasculari-
zation’ [14]. As a result of these changes, the maternal spiral arteries 
undergo transformation from small, muscular arterioles to large 
capacitance and low-resistance vessels, providing an appropriate 
blood flow to the maternal–fetal interface. In PE, due to genetic, 
immunologic and other factors not yet well identified, this pro-
cess is defective. In particular, the physiologic transformation 
of the spiral arteries in the junctional zone of myometrium is 
reduced greatly in the central area of the placental bed, which is 
characterized by a large number of nontransformed myometrial 
spiral arteries, frequently showing obstructive lesions, such as 
acute atherosis and thrombosis [15].
Beside the major pathogenic mechanism, other alternative 
or integrating mechanisms have shown to be involved in the 
pathogenesis of the disease, such as edema and vascular leakage. 
It is well known that systemic endothelial cell dysfunction is asso-
ciated with PE [16,17]: in particular, impaired endothelial barrier 
function consisting in increased vascular permeability is a charac-
teristic vascular response in the disorder. In fact, vasoconstrictor 
response, tendency for coagulation and capillary permeability 
are all enhanced in preeclamptic women; moreover, endothelin 
and fibronectin (markers of endothelial damage) levels are raised 
and surface-adhesion molecules are overexpressed on endothelial 
cells [18,19], confirming the association of disturbed endothelial 
integrity in the vascular system with this condition.
The diagnostic criteria currently used are represented by the 
onset of characteristic clinical symptoms (hypertension and 
proteinuria). In this perspective, the early detection of pla-
cental factors causing abnormal placentation may be useful in 
 asymptomatic women.
Prognostic tools
Since abnormal vascularization and placentation occur, the 
identification of alterations of molecules involved in angiogenic 
mechanisms and placental dysfunction may result as useful 
markers for the early diagnosis of the disease.
During the midtrimester, high serum human chorionic gon-
adotropin (hCG) levels are associated with the risk to develop 
subsequent PE [20,21].
Low levels of PAPP-A may be a marker for identifying preg-
nancies at increased risk to develop PE in the second half of 
pregnancy [22,23]. Therefore, women with low levels of PAPP-A 
during the first trimester are advised to monitor uterine artery 
Doppler by ultrasound from 24 weeks of gestation [24].
Low serum levels of PP13, a placental glycoprotein involved 
in placentation, have been shown in the first trimester of preg-
nancies that subsequently developed PE with a false-positive 
rate of 10%. PP13 showed a prediction rate of 80% as a single 
biochemical marker, and when combined with Doppler ultra-
sound uterine artery PI, the prediction rate increased to 90% 
[25]. Furthermore, low first-trimester serum levels of PP13 may 
be a useful marker for early-onset PE [26].
Since corticotropin-releasing hormone (CRH) and urocor-
tin (Ucn) have vasoactive properties, their increased levels in 
maternal–fetal circulation in hypertensive disorders suggest a 
possible role in the adaptive fetoplacental response to adverse 
conditions [27]. In particular, it was found that increased 
maternal and fetal serum CRH and Ucn levels are frequent in 
pregnancies  complicated by PE [28] and correlate with Doppler 
velocimetry patterns [27].
In the past few years, the ‘angiogenic imbalance theory’ 
emerged to explain the mechanism leading to PE [29].
Activin A and inhibin A are functionally involved in vascular 
adaptive mechanisms of pregnancy as well as cytotrophoblast 
proliferation and differentiation; their placental expression and 
maternal serum levels are elevated in pregnant women with PE 
[30]. A recent study on 4764 subjects demonstrated that mid-
trimester inhibin A concentration of 1.5 multiple of the median 
(MoM) or greater had a sensitivity of 60% and a false-positive 
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rate of 16% for the prediction of PE, showing to be the best 
predictor among other biomarkers studied (maternal serum 
α-fetoprotein, human chorionic gonadotropin and unconju-
gated estriol) [31]. Moreover, Akolekar et al. showed that mater-
nal plasma inhibin A MoM was significantly higher in the early 
and late PE pregnancies (1.55 and 1.24 MoM, respectively) com-
pared with the controls (0.98 MoM) [32]. Therefore, inhibin 
A represents a promising marker to predict the early onset of 
disease, while at-term high levels have been related to severity of 
disease. Compared with inhibin A, activin A seems to be a more 
sensitive marker at 21–25 weeks [33]. The performance of serum 
activin A and inhibin A as predictive markers is improved when 
combined with Doppler ultrasound evaluation of uterine artery 
resistance blood flow at midtrimester [34,35].
Placental VEGF mRNA expression is reduced in gestational 
hypertensive disorders and in the third-trimester placentas of 
pregnancies with PE compared with normotensive controls [36]. 
In a recent study, placentas collected from preeclamptic and 
healthy women delivering by cesarean section showed signifi-
cantly lower level in PE than in controls [37], confirming abnor-
mality of VEGF expression during the disease. Considering the 
biological function of VEGF, involved in angiogenic processes, 
its decreased expression may in part 
explain the structural changes associ-
ated with PE placentas, such as deficient 
growth and differentiation of terminal 
villi and reduced fetal capillary branching.
Soluble fms-like tyrosine kinase-1 
(sFlt-1), a VEGF receptor involved in 
hypoxic/ischemic response, increases 
5 weeks before the onset of PE, without 
modification in the first trimester [38]. 
Alterations in sFlt-1 levels correlate with 
the onset of PE and are higher in women 
with PE and small for gestational age 
(SGA) fetuses [39].
PlGF levels, involved in the invasiveness 
of the extravillous cytotrophoblast [40], are 
significantly lower in women with early-
onset PE compared with controls, point-
ing out how PlGF significantly improved 
the ability of systolic blood pressure at the 
first prenatal visit to predict early-onset 
PE [41].
The sFlt-1/PlGF ratio has been proposed 
as a useful tool for the early identification 
of PE, since a significant increase of the 
ratio occurs prior to the presentation of 
clinical symptoms. Signif icant differ-
ences were observed between controls 
and women with PE, in which circulating 
sFlt-1 levels are fivefold higher and PlGF 
levels are fivefold lower than controls. The 
sFlt-1/PlGF ratio varies during pregnancy, 
but a cut-off value of 85 offers a sensitivity 
and a specificity of 82 and 92%, respectively, for the diagnosis 
of PE during all trimesters of pregnancy, and adding its use in 
clinical practice could improve the management of the disease 
and maternal and neonatal outcome [42]. Moreover, the impor-
tance of the utility of sFlt-1/PlGF ratio has also been recently 
shown in identifying the risk for imminent delivery, as in serum 
of patients with PE/HELLP, its increased concentration is asso-
ciated with the risk of delivering within 7 days [43]. Similar 
results were also shown by Molvarec et al., who highlight the 
decreased PlGF concentration in women with PE associated 
with IUGR and PTD, focusing on the symbiotic role between 
the three diseases [44].
Levels of circulating leptin are increased in women with PE, and 
several studies showed that elevated levels seem to have a prog-
nostic significance for the development of PE before the clinical 
onset of the disease. An association between higher first-trimester 
plasma leptin levels and subsequent PE [45], and that the risk of 
developing PE, is proportional to the increase of serum leptin 
[46]. Moreover, the observation that leptin rises before the clinical 
onset of the disease suggests a possible pathophysiological role of 
this protein. Since it is a potent angiogenic factor, it is responsible 
for increased apoptosis of trophoblastic cells and of blood supply 
Figure 1. Pathogenesis of preeclampsia and endocrine involvement. 
CRH: Corticotropin-releasing hormone; hCG: Human chorionic gonadotropin; 
sFlt-1: Soluble fms-like tyrosine kinase-1.
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to the placenta by neovascularization occurring during PE as a 
compensatory response to the hypoperfused placenta [46].
As with leptin, adiponectin is also an adipocyte-secreted hor-
mone. It has different roles, as it is recognized as pleiotropic, 
insulin-sensitizing, anti-inflammatory and anti-atherogenic 
adipokine. Since low concentrations of adiponectin are associ-
ated with obesity, insulin resistance, Type 2 diabetes, hyperten-
sion [47] and obesity-related malignancies, a possible role has 
been hypothesized in the pathogenesis of PE. However, its role 
has not yet been well defined, as contrasting results have been 
found [48,49].
Soluble endoglin (S-Eng), a modulator of TGF-β signaling 
involved in angiogenesis and regulation of the vascular tone, is 
elevated in PE patients compared with controls, and it is char-
acterized by more elevated levels in case of more severe symp-
toms, reaching the highest values in case of PE complicated by 
HELLP syndrome. In pregnancies ending with PE, a pathologi-
cal increase of S-Eng occurs earlier than in physiologic preg-
nancies and this distinction becomes considerable 9–11 weeks 
before the appearance of clinical symptoms. Therefore, a specific 
prediction cannot be achieved with this analyte alone. For this 
reason, its potential in combination with PlGF and sFlt-1 for 
the prediction of PE has been evaluated, with more encouraging 
results if used together and not as single biomarkers [50].
P-selectin plays a crucial role in inflammatory reactions, as in 
the recruitment and activation of circulating leucocytes, and in 
coagulation processes [51] with increased levels in the peripheral 
blood of PE women [52]. Interestingly, it has recently been shown 
that alterations in the levels of soluble P-selectin before 20 weeks 
of gestation antedate the symptoms. Indeed, this early upregula-
tion of soluble P-selectin seems to be a sign of the early but still 
asymptomatic disturbances of the maternal vascular system [53].
It is well known that in normal pregnancies, nitric oxide  pro-
duction is elevated and this increase seems to be implicated in 
vaso dilatation; however, in pregnancies complicated by PE, its 
production is decreased. Recently, the evidence that nitric oxide 
products are decreased in maternal serum of patients at risk 
for PE between 22 and 26 weeks of pregnancy has suggested 
a possible role to predict the development of preeclampsia [54].
Recent evidence has demonstrated an important role of the 
immune system in the etiology of PE [55]. In this context, an 
activation of the complement system has been widely demon-
strated. Recently, elevated amounts of complement activation 
markers in the systemic circulation during the third trimester of 
pregnancy and, furthermore, in PE patients have been shown, 
with an excessive activation of the terminal pathway in case of 
fetal growth restriction [56]. More elevated serum concentrations 
of heat-shock protein 70, considered a potent activator of the clas-
sical pathway of the human complement system, are present in 
PE patients and its elevated levels are associated with proinflam-
matory changes in circulating cytokine profile, suggesting that 
it may contribute to the development of the excessive systemic 
inflammatory response characteristic of the maternal syndrome of 
the disease [57]. Another evidence of the activation of the immune 
system is demonstrated by the inflammatory environment which 
characterized PE: an increase of proinflammatory cytokines, such 
as IL-6 and TNF-α, of chemokines, as IL-8, IP-10 and MCP-10, 
and of adhesion molecules, such as ICAM-1 and VCAM-1, has 
been highlighted in PE, suggesting the potential role of these 
molecules in endothelial dysfunction [58]. More relevant data with 
regard to prevention of this important disease are those relating to 
markers of pathology, already present midtrimester, such as factor 
B-derived Bb activation fragment from the alternative comple-
ment pathway, which may be used as a marker of the complement 
activation. At 20 weeks of pregnancy, its concentration is more 
elevated in women with subsequent PE as compared with une-
ventful pregnancies, suggesting that it may be an early biomarker 
of the pathogenic events that start in early pregnancy and then 
lead to PE [59]. Furthermore, elevated serum levels of activation 
fragment C3a in midtrimester are an indicator of adverse preg-
nancy outcome, as demonstrated by its elevation in women with 
subsequent PE before 20 weeks of pregnancy [60].
Regarding the prevention of PE, the use of metabolomics seems 
to be promising. This method is able to identify all the metabolites 
in a biological cell, tissue, organ or organism, which are the end 
products of cellular processes. Recently, different studies have 
demonstrated a profound change in the first-trimester metabolite 
profile in women with subsequent early-onset PE, supporting the 
hypothesis that this new science may be critical for the prevention 
of the disease in the future [61,62].
In summary, several placental factors have been investigated 
as potential biomarkers for early diagnosis/prediction of PE. 
Among them, no single biomarker emerged as a risk predictor 
of PE, and the complexity of the pathogenic mechanisms may 
in part explain the impossibility to rely on a single predictor. 
However, although there are currently no arms in our possession 
to prevent this important disease of pregnancy, there are excellent 
 perspectives for future early diagnosis of PE.
Intrauterine growth restriction
Despite the fact that the etiology of IUGR is rather complex and 
characterized by numerous factors, the key point of this disease 
is represented by the abnormalities in placental structure and 
function (Figure 2).
The process of implantation and placentation requires the 
production of several growth factors, cell-adhesion molecules, 
extracellular matrix proteins, hormones and transcription fac-
tors, which often exhibit altered expression within the placenta 
of IUGR pregnancies.
The decrease of villous number, diameter and surface area, as 
well as the decrease in arterial number, lumen size and branching 
are aspects which characterize the placental structure in IUGR 
gestations [63–66]. If during normal pregnancy, extravillous troph-
oblast cells migrate and invade the spiral artery vessel walls within 
the decidua and myometrium, in case of PE and/or IUGR, this 
invasion is restricted to the decidual portion of the spiral arteries, 
with consequent failure of these arteries to become low-resistance 
vessels. This leads to an increased fetoplacental vascular resist-
ance and consequently to decreased blood flow and decreased 
availability of nutrients and oxygen to the fetus.
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A number of factors have been associated with extravillous 
trophoblast invasion, including angiogenic growth factors and 
their respective receptors. While it remains unresolved as to the 
exact mechanism causing deficient trophoblast invasion, angio-
genic growth factors are logical candidates as regulatory molecules 
in placental  development and function [67].
As angiogenesis and vascular transformation are important in 
normal placental development, IUGR is thought to result from 
impaired trophoblast invasion of the maternal spiral arteries in 
early pregnancy, leading to reduced uteroplacental perfusion and 
placental hypoxia [68–70]. It has been hypothesized that placen-
tal hypoxia may stimulate the release of factors by the placenta 
which cause widespread maternal endothelial cell damage and 
derangement of placental angiogenesis. What causes the deficient 
trophoblast invasion remains unknown. In this context, IUGR 
is currently diagnosed by ultrasound measurements (abdominal 
circumference and estimated fetal weight <tenth centile) and 
confirmed postnatally by birth weight below the tenth percen-
tile corrected for gestational age [71]. When IUGR is caused by 
placental insufficiency, the diagnosis is improved including oli-
gohydramnios and/or pathologic umbilical and uterine artery 
pulsatility indices at Doppler examination [72].
Prognostic tools
There are strong indications that angiogenic growth factors related 
to VEGF family may be implicated, especially PlGF and its soluble 
receptor sFlt-1, altered in maternal and fetal serum from preg-
nancies complicated by IUGR. In IUGR pregnancies, sFlt-1 is 
increased, and PlGF is decreased, in both maternal and umbilical 
vein serum. Levels of VEGF are higher and levels of sFlt-1 are 
lower in serum from the umbilical vein and umbilical artery com-
pared with maternal serum. These findings suggest an imbalance 
of angiogenic and antiangiogenic factors in IUGR, with formation 
of an antiangiogenic state in maternal blood altering the terminal 
differentiation of placental capillary loops, and placenta appears 
to play a central role in the release of these  factors [73–75].
Furthermore, in pregnancies complicated by SGA or IUGR, 
altered levels of placental factors, such as glycoproteins, involving 
in growth of the fetoplacenta unit and in trophoblast  proliferation 
were found.
Moreover, low levels of free β-hCG in the first trimester have 
been associated to with growth restriction. For example, Ong 
et al. found that first-trimester maternal β-hCG circulating levels 
below tenth centile of the reference range were associated with 
subsequent development of IUGR [76]. Similarly, Kirkegaard 
et al. demonstrated a strong association between free β-hCG 
levels below 0.3 MoM and SGA fetuses [77]. Finally, in a group 
of 3728 pregnancies affected by one or more of the pregnancy 
complications of low birth weight, IUGR, PTD and stillbirth, 
first-trimester free β-hCG levels below 0.5 MoM showed relative 
risks of 2.3 for developing IUGR [78]. It is still necessary to specify 
that there are conflicting opinions on the role of free β-hCG in 
PE and IUGR [11].
Among women who delivered a IUGR baby, human placental 
lactogen (hPL) remained at low levels throughout gestation. hPL, 
a polypeptide with a somatotropic effect, correlates with placental 
weight and fetal size. Evaluating women at risk for IUGR around 
18 weeks of pregnancy, the prevalence of IUGR associated with 
lower hPL levels is 35% [79]. The physiologic increase in maternal 
serum hPL with advancing gestation does not occur in IUGR 
fetuses, and may be related to the  unsuccessful fetal growth [80].
In summary, IUGR is burdened with significant neonatal mor-
bidity and its diagnosis is still only made through ultrasound. 
Since its diagnosis is often delayed and therapeutic support avail-
able is scarce, further studies investigating new potential bio-
markers for IUGR diagnosis/prediction are necessary. Indeed, 
given its parallelism and its coexistence with PE, in a good per-
centage of cases, the identification of early markers of PE could 
help to detect fetuses at risk of IUGR.
Preterm delivery
PTD is a syndrome characterized by a complex pathogenesis 
(Figure 3). The most common lesions found in the placenta of 
patients with spontaneous preterm parturition are those of acute 
inflammation (acute chorioamnionitis and funisitis). Vascular 
lesions are the second most common histologic appearance in the 
placenta of these patients. Placentas of patients with preterm labor 
and intact membranes show a greater degree of failure of trans-
formation of the spiral arteries in the myometrial and decidual 
segments compared with women with term labor. However, this 
aspect is even more relevant in patients with PE. Several placen-
tal vascular lesions have been described in patients with preterm 
premature rupture of membranes (PROM), as failure of physi-
ologic transformation of the decidual segment of the spiral arter-
ies, thrombosis and atherosis. Thus, patients who deliver preterm 
may be classified in two major categories: patients with acute 
inflammatory lesions and patients who deliver preterm, but at a 
later gestational age, in whom the principal lesions are vascular. 
Figure 2. Pathogenesis of intrauterine growth restriction 
and endocrine involvement.  
hCG: Human chorionic gonadotropin; hPL: Human placental 
lactogen; sFlt-1: Soluble fms-like tyrosine kinase-1.
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Maternal vascular lesions, leading to uteroplacental ischemia, 
may be responsible for a preterm labor. Although this process is 
still largely unclear, there are some assumptions. For example, 
thrombin is suggested to play an important role in the activa-
tion of the common pathway of parturition, in particular when 
uteroplacental ischemia is severe enough to cause decidual necro-
sis and hemorrhage. Deficient angiogenesis, thrombosis, and/or 
insufficient physiologic transformation of the spiral arteries can 
cause ischemia of the placenta and the uterus [3,4].
Uteroplacental ischemia has recently been implicated as a 
mechanism of disease in preterm PROM, as well as in preterm 
parturition with intact membranes. Failure of physiologic trans-
formation, decidual thrombosis and other vascular lesions have 
been identified in a substantial portion of these patients, as result 
of the failure of physiologic transformation in the myometrial 
segments of the spiral arteries. Herein, it is possible to add pre-
term PROM to the group of obstetric syndromes where abnormal 
placentation has been documented [10].
As an adaptive mechanism to these pathological changes, 
placenta produces and releases several factors, in the maternal 
 circulation, that can be used as diagnostic or predictive markers 
of PTD and some of them as therapeutic tools.
Diagnostic tools
Although the diagnosis of PTD is mainly clinical, currently the 
use of biochemical and biophysical tools is of fundamental sup-
port in the routine practice. In symptomatic and asymptomatic 
patients at risk of PTD, vaginal digital examination for assessing 
the cervix is subjected to large variation among examiners [81], and 
therefore, the measurement of cervical length (CL) by transvagi-
nal ultrasonography represents a more reliable tool in detecting 
patients at risk of PTD [82]. In the highest risk women, a CL of 
25 mm has a positive-predictive value of 70% at 14–18 weeks and 
of 40% at 18–22 weeks for PTD <35 weeks of pregnancy [83]. In 
addition, fetal fibronectin (fFN) testing has shown to be a promis-
ing predictor of PTD. A positive fFN test in vaginal fluids is the 
most accurate investigation in predicting spontaneous preterm 
birth (PTB) within 7–10 days among women with symptoms 
of threatened PTD and improves the predictive value of cervical 
ultrasonography to identify patients at risk [84]. A fFN positive test 
represents a powerful marker of PTD when measured at or after 
22–24 weeks of gestation in asymptomatic high-risk women [85].
In summary, with regard to the complex etiopathogenesis of 
PTD syndrome, the combination of biochemical markers, such 
as fFN, and biophysical parameters, primarily transvaginal CL, 
may help to better diagnose this condition and provide a valuable 
tool for the identification of high-risk patients.
Prognostic tools
Although the presence of changes in the placental vascular bed 
represents the latest findings in order to better understand the 
mechanisms that lead to PTD, this complex syndrome has been 
understood over the years by analyzing the changes of both steroid 
and stress placental hormones.
Among steroids, the association between estriol and PTD 
has long been investigated. The salivary estriol profile is simi-
lar between women with term deliveries and PTDs, showing a 
characteristically increase throughout the second half of preg-
nancy, increasing approximately 3 weeks 
before parturition. The primary difference 
between women who gave birth at term 
and those who had spontaneous PTD 
was in the timing of the estriol elevation 
[86]. Salivary estriol levels were higher in 
patients delivered preterm than in women 
delivered at term. This difference appeared 
as early as at 24–26 weeks of gestation and 
continued until 34–36 weeks [87]. In symp-
tomatic women, salivary estriol is associ-
ated with an increased risk of delivery 
within 2 weeks, but its clinical utility as 
a routine screening test to predict preterm 
labor in asymptomatic women has not been 
established [88]. Recently, due to increased 
knowledge of the hormonal changes under-
lying both term deliveries and PTD, the 
assessment of the estriol/estradiol ratio may 
be a useful marker to predict PTD. In fact, 
the increase of estriol production is related 
to the timing of the onset of labor, however, 
a pivotal event of parturition is represented 
by a change in the ratio of the estradiol 
and estriol as labor approaches, leading to 
a more than tenfold excess of estriol. Since 
Figure 3. Pathogenesis of preterm delivery and endocrine involvement.  
CRH: Corticotropin-releasing hormone; phIGFBP-1: IGF binding protein 
nonphosphorylated isoform; Ucn: Urocortin.
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estriol/estradiol ratio increased in the month before delivery, cre-
ating an estrogenic environment at the onset of labor, the estriol 
increase and the altered estriol/estradiol ratios may be clinically 
useful in predicting PTD [89].
It has been known for long that the hypothalamic–pituitary–
adrenal (HPA) axis hormones play a significant role in the mech-
anisms of response to the stress of delivery. Placental CRH is 
thought to play a crucial role in the regulation of fetal maturation 
and the timing of delivery, and it has also been implicated in the 
control of fetoplacental bloodflow.
CRH and Ucns play an important role in pathogenesis PTD, 
as shown in the past by in vitro and in vivo studies on placental 
explants. Many lines of evidence support the involvement of pla-
cental CRH in the mechanisms controlling the onset of labor, 
both at term or preterm. The evolution of maternal serum CRH 
concentrations parallels the CRH curve of normal pregnancy 
but the levels are higher when labor occurs preterm [90]. CRH is 
involved in pathogenetic mechanisms leading to PTD in which 
inflammatory and infective pathways represent central events 
[91]. Maternal plasma CRH levels at midgestation are higher in 
women who subsequently have spontaneous PTD than in preg-
nant women delivering at term [92]; moreover, women affected 
by threatened preterm labor present higher plasma CRH lev-
els when delivering within 24 h than when delivering later [92]. 
Measurement of maternal serum CRH would not satisfy the 
requisites of a screening test for PTD in a low-risk population, 
although it should be considered a potential marker to be used in 
populations with a higher risk [93]; however, its clinical relevance 
has still to be confirmed.
Also maternal plasma Ucn levels are increased in PTD [94]. Ucn 
directly enhances myometrial contractility by augmenting myo-
metrial contractile response to prostaglandins and activating the 
signaling pathways that regulate myometrial contractility [95]. In 
women with threatened preterm labor, maternal plasma Ucn levels 
are increased in patients who experience preterm labor before 
34 weeks of pregnancy, and among women laboring pre maturely 
are higher in those delivering within 7 days, compared with those 
delivering later [94]; therefore this measurement provides a promis-
ing new biochemical marker which may add significant prognostic 
information for predicting PTD among women at risk.
Changes of other placental molecules, such as glycoproteins, 
were investigated in association with PTD, showing a correla-
tion which has proven to be less viable than that obtained with 
other hormones; in particular, lower levels of PAPP-A in maternal 
serum between 10 and 13 weeks of pregnancy are associated with 
a higher risk of PTD [96], while elevated maternal serum hCG 
levels in the second trimester are associated with an increased risk 
for PTD in low-risk pregnancies [97,98], also demonstrating an 
increased risk with higher levels of hCG [97]. Moreover, hCG con-
centrations in cervicovaginal secretions between 24 and 36 weeks 
of gestation, at the cut-off value of 50 mUI/ml, can predict PTD 
before 34 weeks with a sensitivity of 50% and a specificity of 
87% [99].
Maternal plasma PTX3 concentration is significantly elevated 
during labor at term and in the presence of spontaneous preterm 
labor or preterm PROM, suggesting that the increased PTX3 
concentration is part of the physiologic or pathologic activation of 
the proinflammatory response in the maternal circulation during 
the process of labor, both at term or preterm [100].
While there is no significant association between maternal IGF 
and PTD, there is much literature about the association between 
IGF binding protein nonphosphorylated isoform (phIGFBP-1) 
and PTD [101]. A positive cervical phIGFBP-1 conferred a sig-
nificantly increased risk of delivery before 34 weeks in women 
with a cervix ≤30 mm, and a significantly increased risk of deliv-
ering within 7 days in the subgroup of women with a CL of 
20–30 mm [102] with high negative-predictive value (88%) and a 
low  positive-predictive value (24%) [101]. Since the most common 
cause of PTD is intrauterine infection, it has been hypothesized 
that the reduction of IGF may be caused by increased production 
of inflammatory mediators [103].
Concerning the unquestionable importance of infection/
inflammatory processes in the pathogenesis of PTD, through-
out the years, several cytokines and interleukins have been 
 investigated as possible biomarkers for PTD.
In particular, IL-2, -6, -8, and -10, TNF-α, granulocyte colony-
stimulating factor, stromal cell-derived factor-1α, IFN-γ, matrix 
metalloproteinase-8, secretory leukocyte proteinase inhibitor, 
soluble VCAM-1, soluble ICAM-1, C-reactive protein, ferritin 
and alkaline phosphatase have been more or less correlated with 
the PTD [104,105].
Among these, IL-6 demonstrates the greatest predictive value, 
since in asymptomatic women at 22–25 weeks its concentration 
in cervical fluid is significantly in case of subsequent PTD and 
in symptomatic women, affected by threatened PTD, it dem-
onstrates ability to predict delivery within 2 and 7 days with a 
sensitivity and specificity of 60 and 77%, respectively,  for pre-
dicting delivery within 2 days, and 62 and 80%, respectively, 
for predicting delivery within 7 days [106]. Furthermore, also in 
amniotic fluid, its concentration in asymptomatic women under-
going mid-trimester amniocentesis is higher in women with subse-
quent spontaneous PTD within 32 weeks of gestation, than those 
who delivered at term, showing an association of IL-6 levels in 
amniotic fluid and early PTD [107].
In summary, it is well known that the early identification of 
women at risk of giving birth prematurely would allow to activate 
possible preventive measures to reduce the impact of this condi-
tion. Since spontaneous PTD is frequently preceded by threat-
ened PTD, characterized by the presence of uterine contractility 
in absence of cervical changes at the obstetric examination, the 
identification of those experiencing PTD after diagnosis of threat-
ened PTD would allow the optimization of obstetric manage-
ment in symptomatic women. Biomarkers identified so far lack 
enough accuracy to represent single predictors for PTD; studies 
conducted to identify them are heterogeneous as far as population 
to which address them as predictive biomarkers. Therefore, the 
combination of them with other predictors, such as ultrasound 
parameters (CL, funneling) together with a better identification 
of risk factors, would improve the estimation of the risk of PTD 
both in symptomatic and asymptomatic women, and allow an 
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optimization of the clinical practice, by addressing only those at 
high risk to therapeutic or preventive measures.
Therapeutic tools
Interestingly, the central role that placental hormones play in the 
pathogenesis of PTD is also reflected in the therapeutic  appearance 
of the disease.
The use of 17-α-hydroxy-progesterone caproate supplementation 
has been approved during pregnancy to reduce the risk of recur-
rent PTD in women with a history of at least one prior spontane-
ous PTD. In addition to the weekly intramuscular administration 
in women with a history of previous PTD, there is also evidence 
that in cases of cervical shortening (<15 mm) diagnosed by trans-
vaginal ultrasound prior to 24 weeks women may also benefit of 
17-α-hydroxy-progesterone caproate administration [108].
Progesterone treatment is also recommended in singleton preg-
nancies of women with no prior PTD and CL <20 mm at 24 weeks; 
by vaginal progesterone is associated with reduction in PTD and 
perinatal morbidity and mortality [109].
Another treatment largely used in women with PTD is the ante-
natal administration of synthetic glucocorticoids for accelerating 
fetal lung maturation and decreasing neonatal mortality and mor-
bidity in infants born before 34 weeks of gestation [110]. The admin-
istration of antenatal corticosteroids in women at risk of imminent 
PTD is associated with decreased neonatal morbidity and mortality 
[111], improving fetal lung maturation by promoting surfactant syn-
thesis, increasing lung compliance, reducing vascular permeability 
and generating a greater response to postnatal surfactant treatment. 
The maximal effectiveness in preventing neonatal complications of 
prematurity is when delivery occurs within 2–7 days after adminis-
tration [112], and a single course of antenatal corticosteroids should 
be considered routine for all preterm deliveries [113].
Although the short-term outcomes and benefits of exposure to 
single and repeated doses of synthetic glucocorticoids is reassuring, 
there is reason for caution in extrapolating these findings for the 
long term based on the reported adverse long-term and perma-
nent changes on the HPA axis [110]. Exposure to excess levels of 
endogenous and exogenous glucocorticoids can lead to permanent 
modification of HPA function and stress-related behavior, caus-
ing dysregulation of the fetal and neonatal HPA axis and life-long 
consequences, such as adaptation to stress, cognition, behavior and 
the cardiovascular and immune responses [114].
Conclusion
After an overview of the literature on the etiopathogenetic 
 mechanisms taking part in the development of the main obstetric 
syndromes, PE, IUGR and PTD, we have shown how placental 
dysfunction plays a common and central role in all these diseases. 
Several placental factors have been studied as potential diagnostic 
and predictive biochemical markers, although none of them can 
be considered as a single biomarker to early identify either women 
affected by or those at risk for the development of the syndromes. 
In such a complex scenery, we therefore show how a greater knowl-
edge and awareness of the etiologic and pathogenetic mechanisms 
may be useful for the identification of novel biomarkers or at least 
for the  strategic combination of them with other tools (ultrasound 
parameters, risk factors) to improve prediction and prevention of 
these diseases, still burdened by a significant rate of maternal and 
fetal morbidity.
Expert commentary & five-year view
PE, IUGR and PTD are considered the major obstetric syn-
dromes, complicated by significant maternal and fetal morbid-
ity and mortality. Despite new diagnostic techniques and new 
therapies, their incidence in recent years has not diminished.
The understanding of the pathogenetic mechanisms involved 
in these diseases may offer new tools for the future. In particu-
lar, the altered placental vascularization associated to the altered 
production of placental factors suggests a possible use as diagnos-
tic or predictive markers. The fibronectin test and phIGFBP-1 
are currently used as diagnostic testing. A possible prognostic 
role is supposed for sFLT-1/PlGF for PE and for CRH and Ucns 
for PTD.
The combination of both biochemical and biophysical markers 
is a developing method for the prevention of the major obstetric 
syndromes.
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Key issues
• Placental disorders and impaired placentation are common mechanisms for the obstetric syndromes.
• Preeclampsia and intrauterine growth restriction are characterized by the dysfunction of placental perfusion, of endothelium and of 
placental hormones and metabolism.
• Preterm labor is a syndrome resulting from infection/inflammation, stress and altered vascularization in placental–fetal unit.
• Placental factors may be used as diagnostic or prognostic markers for the obstetric syndromes, in combination with biophysical markers.
• A possible therapeutic implication may be hypothesized.
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